Luis E Raez
Luis E Raez, MD is an expert in Oncology at Sarasota Memorial Health Care System (United States). As of October 2026, ScienceLeadR ranks Luis E Raez in the top 1% of experts worldwide for Bronchial Neoplasms, Thoracic Neoplasms and Lung Neoplasms. Luis E Raez has authored 371 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 1 of them ongoing. SLR score: 1,509 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Biochemistry - Pulmonology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Luis E. Raez, MD, FASCO, FACP, FCCP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the Vice-President of the Florida Society of Clinical Oncology (FLASCO) 2017-19 and President 2019-2021. He was an Associate Professor of Medicine, Epidemiology and Public Health, and a Co-Director of Thoracic Oncology at Sylvester Cancer Center/University of Miami for 10 years (2001-2011). He has expertise in medical oncology in the area of lung cancer, cancer disparities and liquid biopsies, He designs phase I-III clinical trials with new targeted agents and immunotherapy. Dr. Raez does translational research and clinical research. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America, Africa and Asia. He has been the Chairman of the IASLC Latin American Group (LATAM) since 2018; Chair of the IASLC Membership Committee from 2015-2018; International Chair of the IASLC-Latin-American Meeting (LALCA) since 2014; Chairman for the "Miami Best of ASCO" since 2014, Chair and Founder of the "Miami Cancer Meeting (MCM)" since 2002, Co-Chairman at the "Puerto Rico Fall Cancer Symposia (FCS)" since 2010. He is one of the founder members of Oncology Latin-American Association (OLA). He is American Board Certified in: Internal Medicine and Medical Oncology. He is board eligible in Hematology. He is a member and serves in several committees at: AACR, OLA, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, SLACOM, FLASCO among other institutions.
Organizations
Career arc: 1998 - 2026
Number : 371
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions. PMID 42737745 — cells, genes, lung, progression-free survival, neoplasms, carcinoma, non-small-cell lung, gene fusion, lung neoplasms, small cell lung carcinoma, therapeutics | Int J Mol Sci | 2026 | 0 |
| Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC. PMID 42532338 — research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna | J Thorac Oncol | 2026 | 1 |
| Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Bispecific Antibodies in Oncogene-Driven Non-Small-Cell Lung Cancer: Evolving Roles in Treatment Sequencing and Resistance Management. PMID 42511594 — oncogenes, cells, lung, antibodies, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, biomarkers, central nervous system, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, antibodies, bispecific | Int J Mol Sci | 2026 | 0 |
| The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC. PMID 42512264 — oncogenes, antibodies, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, therapeutics, antibodies, bispecific | Cancers (Basel) | 2026 | 0 |
| KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. PMID 42511798 — cells, lung, genes, ras, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics, tumor microenvironment, drug resistance | Int J Mol Sci | 2026 | 5 |
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC NCT04919811 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, carcinoma | Phase 2 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map